Lead Researcher Says Hepatitis B Vaccine Trial in Guinea-Bissau Newborns Will Not Proceed

5.0 · 11d ago · WORLD

The Facts

  • Guinea-Bissau judicial police searched the Bandim Health Project's facilities in Bissau on Monday and seized a batch of hepatitis B vaccines; the government now controls the vaccines. ✓2 · The Guardian, Ars Technica
  • Police said the operation aimed at clarifying circumstances related to the vaccine batch, and that the seizure does not in itself indicate irregularities in the vaccines' quality, safety or effectiveness. ✓2 · The Guardian, Ars Technica
  • The trial was to be funded by a $1.6 million US CDC grant to Bandim researchers Peter Aaby and Christine Stabell Benn. ✓2 · The Guardian, Ars Technica
  • Guinea-Bissau Health Minister Quinhin Nantote told the Guardian last week that reports the trial would move forward were 'not even remotely true'. ✓2 · The Guardian, Ars Technica
  • Lead researcher Frederik Schaltz-Buchholzer said on LinkedIn that the hepatitis B vaccine trial 'will not move forward in Guinea-Bissau', stating 'we were not given the necessary governmental approval'. The Guardian only
Dive deeper · 8 more factsShow less
  • Another $1.6 million was to come from private partners including the Pershing Square Foundation and the Bluebell Foundation, for a total of $3.2 million. The Guardian only
  • The study would have denied hepatitis B vaccine to 7,000 newborns in their first six weeks; about one in five adults in Guinea-Bissau has the virus. The Guardian only
  • WHO recommends all infants receive a first hepatitis B dose as soon as possible after birth, preferably within 24 hours; spokesperson Tarik Jašarević earlier said any study denying the vaccine is 'unethical and exposes newborns to serious and potentially irreversible harm'. The Guardian only
  • Guinea-Bissau currently plans to offer the universal hepatitis B birth dose in 2028, according to vaccines expert Paul Offit. The Guardian only
  • Bandim posted a national ethics committee approval dated 14 July, and a Danish research ethics committee approved the study earlier this month. The Guardian only
  • The CDC announced the grant in December; plans were halted in January after criticism of the trial design, and Rolling Stone reported the CDC set aside another $1.6 million in late September. Ars Technica only
  • Aaby and Stabell Benn are under investigation by Danish authorities for alleged scientific misconduct. Ars Technica only
  • The CDC and the Danish researchers did not respond to the Guardian on whether the funding would be used to vaccinate all newborns in Guinea-Bissau. The Guardian only

Context

The lead researcher of a planned hepatitis B vaccine trial among newborns in Guinea-Bissau said the study will not proceed in the country, citing lack of governmental approval. The announcement follows a police search of the Bandim Health Project and seizure of vaccine doses on Monday.

The trial, partly funded by the US CDC, drew criticism from the WHO and vaccine experts, who said withholding a recommended birth dose from participants was unethical. Researchers had hypothesized that adding the hepatitis B vaccine to live vaccines like BCG could dampen their broader mortality benefit.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 2.

6 News Editor The concrete event is the cancellation of a controversial trial (denying vaccine to 7,000 newborns) plus a police seizure of vaccine batches, which is newsworthy with moderate public health and policy impact but affects a limited population directly.
6 Policy Expert The story reports a concrete outcome, the cancellation of a federally funded trial after a government-approval denial and a police seizure of vaccine doses, which is newsworthy with moderate public-health and governmental significance but limited to a single study and country.
6 Critical Reader The concrete event is the cancellation of a controversial trial that would have withheld hepatitis B birth doses from 7,000 newborns, backed by a police seizure of vaccine batches, which is newsworthy with moderate public health impact but limited to one study in one country.
5 Global Affairs Analyst A controversial trial's cancellation after a police seizure of vaccine doses is a concrete development with ethical and public-health implications, but its scope is limited to one small study in a single country, so it sits in the moderate range.
4 Business Analyst A cancelled vaccine trial with a $3.2M budget and a police seizure of vaccine batches is a notable, controversial health-policy event, but its direct economic and population impact is limited and it is largely a halted research study rather than a broad market or regulatory shift.
4 Science & Tech Analyst The story reports a concrete outcome, cancellation of a controversial vaccine trial halted by government non-approval and a police seizure of vaccine batches, but its impact is limited to a single study in one small country, with no broad population-level effect.
4 Informed Citizen The concrete event is the cancellation of a controversial trial that was never started, with a police seizure of vaccine doses that the police say does not indicate quality problems, so the direct impact on ordinary people is limited though it touches on newborn vaccine policy and ethics.

Sources (3)

← All stories